What’s Trending?

A late-stage trial assessing Ipsen and Exelixis' Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed. [...]
Wed, Jan 17, 2018
Source PharmaTimes
The Government's 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found. [...]
Wed, Jan 17, 2018
Source PharmaTimes
Pfizer is facing tough ALK-positive lung-cancer competition with Xalkori, and the latest move from England's cost watchdogs isn't making it any easier for the company to branch out. [...]
Wed, Jan 17, 2018
Source FiercePharma
Valeant and Pershing Square are one step closer to putting years of insider trading allegations in the past. [...]
Wed, Jan 17, 2018
Source FiercePharma
Boehringer Ingelheim's Gilotrif is up against some stiff competition in the EGFR lung cancer space. But this week, it snagged a label update that will widen its reach. [...]
Wed, Jan 17, 2018
Source FiercePharma
Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field. [...]
Wed, Jan 17, 2018
Source FiercePharma
Regulators on both sides of the Atlantic are undertaking speedy reviews of Novartis' CAR-T therapy Kymriah. [...]
Wed, Jan 17, 2018
Source PharmaTimes
Pfizer's Xalkori has been turned away by the National Institute for Health and Care Excellence to treat ROS1-positive advanced non-small cell lung cancer. [...]
Wed, Jan 17, 2018
Source PharmaTimes
Novartis
Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k) pathway, for proposed biosimilar adalimumab to the reference medicine, Humira®*. [...]
Tue, Jan 16, 2018
Source WorldPharmaNews
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells. There is a critical need to non-invasively and remotely manipulate cells at a distance, particularly for translational applications in animals [...]
Mon, Jan 15, 2018
Source WorldPharmaNews
FDA
The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP [...]
Fri, Jan 12, 2018
Source WorldPharmaNews
Novartis
Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the Executive Committee of Novartis, effective February 1, 2018. She will be based in Basel. Mrs. Barrett succeeds Bruno Strigini who decided to retire from Novartis [...]
Thu, Jan 11, 2018
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews